core-g28v2 60mer mrna vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2021 (NCT05001373)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05001373 | Phase 1 | Oct 15, 2021 | Emory University, George Washington University, International AIDS Vaccine Initiative, Moderna Therapeutics, University of Texas, San Antonio, University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| George Washington University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Moderna Therapeutics | For profit | 1 | 0 | 1 | 2021 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1